Register or Sign in to Save this opportunity, or Send an Inquiry.
Anti-Inflammatory Agent Showing Excellent Early Promise in Eye Models for Uveitis
Formuli United Kingdom flag United Kingdom
Abstract ID:
Recently gaining patent approval, this product is for Uveitis and Irritable Bowel Syndrome.
Send an Inquiry

Considerable in-vitro data has been generated showing this product to have excellent potential as an anti-inflammatory agent.  The company have selected Uveitis as a target indication and have Irritable Bowel Syndrome as a follow-up.

Looking for partners to move into the clinic.


Type of Business Relationship Sought
Funding, joint-venture, out-licensing
Last Updated Aug 2016
Technology Type MECHANISM
Phase of Development PRECLINICAL

Opportunity Contact